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Clinical Characteristics of MuSK 
Antibody-positive Myasthenia 
Gravis in Taiwan
Yung-Chuan Huang,1 Jiann-Horng Yeh,1,2 Hou-Chang Chiu,1,2 Wei-Hung Chen1,3*
Circulating antibodies of the acetylcholine receptor (AchRAb) are detectable in most patients with generalized
myasthenia gravis (MG). A newly discovered antibody against muscle-specific kinase (MuSKAb) has been
detected in 40–70% of AchRAb-negative MG patients. We report a series of Taiwanese MuSKAb-positive
patients, and compare their clinical features with MuSKAb-negative patients and also with MuSKAb-positive
Caucasians. Five out of 44 seronegative generalized MG patients (11.4%) were positive for MuSKAb.
Patients with MuSKAb tended to have severe disability and bulbar involvement, and more often experienced
crisis or impending crisis. Although all of these patients showed an initial response to immunosuppres-
sant therapy, they had greater disability at follow-up. The clinical features of Taiwanese MuSKAb-positive
patients were not different from those of Caucasians, except for a lower prevalence. [J Formos Med Assoc
2008;107(7):572–575]
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BRIEF COMMUNICATION
Myasthenia gravis (MG) is an autoimmune disease
that affects neuromuscular transmission and re-
sults in muscular weakness. Autoantibodies to
acetylcholine receptors (AchRAb) are detected in
the sera of 80–90% of patients with generalized
MG.1 However, the sera of around 40% of ocular
MG patients and around 10% of generalized MG
patients have no AchRAb: such cases are termed
seronegative MG (SNMG). Clinical and experimen-
tal evidence indicates that SNMG is nevertheless
caused by serum factors.2,3
Hoch et al first reported a serum IgG antibody
against the muscle-specific kinase (MuSKAb) caus-
ing clinical weakness in SNMG patients.4 In the
past, MuSKAb has been detected in 40–70% of
Caucasian SNMG patients.4–9 It is reported that the
MuSKAb-positive patients are more often women,
younger at the onset of MG, have predominant
cranial and bulbar muscle weakness and a higher
frequency of respiratory failure than the MuSKAb-
negative patients.5 Although these patients may
respond to immunotherapy and plasma exchange,
they tend to have residual facial and bulbar
weakness.
There are only a few reports of MG patients
with MuSKAb in Asia. Ohta et al10 found that seven
out of 17 (41%) and Nemoto et al11 found that
four out of 13 (31%) generalized SNMG patients
had MuSKAb in Japan. The prevalence and clinical
features of MuSKAb were similar to those of
Caucasians. In contrast, we reported a very low per-
centage of MuSKAb (4%) in 26 Taiwanese SNMG
patients.12 There are distinct differences between
Chinese and Caucasian MG patients in terms of
clinical features and association with human
leukocyte antigen.13,14 For MuSKAb-positive MG
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patients, such racial differences may still exist.
Here, we describe and compare clinical character-
istics in a series of Taiwanese MuSKAb positive and
negative SNMG patients.
Methods
This study comprised 44 consecutive generalized
SNMG patients, 12 males and 32 females, aged
3–73 years. Diagnosis was based on typical clinical
features and a positive pharmacologic response
to oral pyridostigmine or corticosteroids, and was
confirmed by electrodiagnostic tests. Patients with
other autoimmune diseases or an uncertain clinical
course were excluded. All patients were negative
for AchRAb using a standard radioimmunopre-
cipitation assay.
All patients received anticholinesterase ther-
apy. Eighteen of these patients had received im-
munosuppressants, including a corticosteroid or
azathioprine, and 16 patients had undergone
thymectomy. The thymic pathology included hy-
perplasia in 12 patients, atrophy in three patients,
and thymoma in one patient. Thirteen patients
received plasmapheresis for myasthenic crisis. The
clinical status was evaluated according to the
MGFA (Myasthenia Gravis Foundation of America)
clinical classification.15
Each patient gave informed consent. The ethical
committee of Shin-Kong Wu Ho-Su Memorial
Hospital approved this study.
MuSK antibody assay
MuSK antibodies were detected by standard ra-
dioimmunoprecipitation (RSR Ltd., Cardiff, UK).
Five μL of serum was incubated with 50 μL of
125I-MuSK for 4 hours. Further immunoprecipi-
tation was done with 50 μL of sheep antihuman
immunoglobulin G for 1 hour. Pellets were counted
on a gamma counter. Serial dilutions were tested
for all MuSKAb-positive samples.
Statistical analysis
We compared clinical features, disease progression,
response to treatment, and residual symptoms
between MuSKAb-positive and MuSKAb-negative
patients. Differences were compared by the χ2
test for categorical variables or by two-sample 
t tests for continuous variables.
Results
Four women and one man out of 44 SNMG pa-
tients (11.4%) had anti-MuSKAb. Four patients
suffered from respiratory or pharyngeal muscles
weakness, and one patient presented with mainly
ocular symptoms. The four patients all had suf-
fered from MG crisis, necessitating plasmaphere-
sis and long-term immunotherapy. One patient 
received thymectomy for thymus hypertrophy 
on mediastinum CT. The pathology was thymus
hyperplasia.
Females predominated in both MuSKAb-
positive (4/5) and MuSKAb-negative groups
(28/39). Mean age of onset was slightly older in the
MuSKAb-positive group (48.6 ± 13.5 years) com-
pared to the MuSKAb-negative group (34.6 ± 16.8
years) (p = 0.05). In contrast to MuSKAb-negative
patients whose presentation at disease onset varied
widely, MuSKAb-positive patients had exclusively
ocular symptoms at onset. However, as disease
progressed, 4/5 (80%) patients had maximum
disability (MGFA ≥ 3) and 5/5 (100%) MuSkAb-
positive patient had bulbar symptoms. MuSKAb-
positive patients had more severe disability 
(p = 0.003) and bulbar involvement (p = 0.05).
Four MuSKAb-positive patients experiencing crisis
or impending crisis received plasmapheresis 
(p = 0.005). Although MuSKAb-positive patients
showed an initial response to immunosuppres-
sant therapy, they had greater disability (MGFA
classification ≥3) at follow-up (p=0.004; Table 1).
Discussion
In this Taiwanese SNMG series, the prevalence of
MuSKAb (11.4%) was lower than in Caucasian
patients. There are wide variations in the preva-
lence of MuSKAb among different ethnic groups
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(Table 2).4–11,15 In most large studies in Caucasians,
the prevalence was generally around 30–40%;
however, it varied from as low as 5% among
Swedes up to 47% among Italians. In Asians, Ohta
et al reported 41% MuSKAb-positivity among
Japanese SNMG patients,10 and Lee et al reported
26.7% MuSKAb-positivity among Koreans.16 Be-
cause the patient numbers of these studies were
relatively small, it is difficult to estimate the true
prevalence.
Similar to previous studies, we found that
MuSKAb-positive patients were predominantly
female. Although Evoli et al5 reported a younger
age of onset in the MuSK-positive patients, the
Japanese group found no such age difference.11
Most of the large series reported an onset age of
approximately 35 years. In contrast, the age at on-
set of our MuSKAb-positive patients (48.6 ± 13.5)
was later than in our MuSKAb-negative patients
(34.6 ± 16.8) or of MuSKAb-positive patients from
other series.
MuSKAb-positive patients are more likely to
have ocular and bulbar weakness,3–6 but isolated
bulbar or neck muscle weakness has also been
Table 1. Clinical characteristics of MuSK antibody (MuSKAb)-negative and MuSKAb-positive patients with
generalized myasthenia gravis without acetylcholine receptor antibodies in serum
MuSKAb-negative (n = 39) MuSKAb-positive (n = 5) p
Female gender 28/39 (71.8%) 4/5 (80%) NS
Onset age (yr) 34.6 ± 16.8 48.6 ± 13.5 0.0499
Ocular onset 19/39 (48.7%) 5/5 (100%) NS
Bulbar onset 12/39 (30.8%) 0/5 (0%) NS
Bulbar symptoms during course 21/39 (58.9%) 5/5 (100%) 0.0481
Bulbar symptoms at last visit 9/39 (23.1%) 3/5 (60%) NS
Maximum disability (MGFA ≥ 3) 7/39 (18%) 4/5 (80%) 0.0026
Plasmapheresis 8/39 (20.5%) 4/5 (80%) 0.0049
Immunotherapy 14/39 (35.9%) 4/5 (80%) NS
Thymectomy 15/39 (38.5%) 1/5 (20%) NS
Improvement after treatment 26/39 (66.7%) 5/5 (100%) NS
NS = not significant; MGFA = Myasthenia Gravis Foundation of America clinical classification.
Table 2. Clinical characteristics of MuSKAb-positive patients, with generalized myasthenia gravis without
acetylcholine receptor antibodies in serum, compared to earlier reports
Author/Country
This study/ Evoli et al5/ Sanders et al7/ Lavrnic et al9/ Nemoto et al11/
Taiwan Italy USA Serbia Japan
MuSKAb prevalence 5/44 (11%) 37/78 (47%) 12/32 (38%) 17/55 (31%) 4/13 (31%)
Female (%) 80 78 100 88 100
Mean age of onset (yr) 48.6 35 38.4 35.6 33
Ocular onset 5/5 (100%) ND 5/12 (42%) 11/17 (65%) ND
Bulbar onset 0/5 (0%) ND 5/12 (42%) 12/17 (71%) ND
Bulbar symptoms 5/5 (100%) 37/37 (100%) 11/12 (92%) 14/17 (83%) 3/4 (75%)
during course
Plasmapheresis or intravenous 4/5 (80%) 29/37 (78%) 10/12 (83%) 6/17 (35%) ND
immunoglobulin
Immunotherapy 4/5 (80%) 35/37 (95%) 12/12 (100%) 17/17 (100%) 4/4 (100%)
Thymectomy 1/5 (20%) 15/37 (41%) 7/12 (58%) 9/17 (53%) 4/4 (100%)
Improvement after treatment 5/5 (100%) 32/37 (87%) 12/12 (100%) 16/17 (94%) ND
ND = not described.
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reported.7 There was no significant difference in
the patterns of muscle involvement and severity
of disease at disease onset in our series. However,
as disease progressed, patients with MuSKAb had
more bulbar involvement and more severe weak-
ness. They more often needed plasmapheresis or
intravenous immunoglobulin and subsequent
long-term immunotherapy. As compared to
other series, our patients had exclusively ocular
onset; the clinical presentations and disease
course were nevertheless similar. All patients
showed a beneficial response to immunotherapy.
In summary, our patients had mainly cranial
and bulbar muscle involvement, a high frequency
of respiratory failure, and relatively mild limb
weakness. The clinical features of Taiwanese
MuSKAb-positive patients were similar to those of
Caucasian patients except for a lower prevalence.
Acknowledgments
This work was supported, in part, by a research
grant (92-2314-B-341-002) from the National
Science Council of Taiwan.
References
1. Vincent A, Newsom-Davis J. Acetylcholine receptor anti-
body as a diagnostic test for myasthenia gravis: results in
153 validated cases and 2967 diagnostic assays. J Neurol
Neurosurg Psychiatry 1985;48:1246–52.
2. Mossman S, Vincent A, Newsom-Davis J. Myasthenia
gravis without acetylcholine receptor antibody: a distinct
disease entity. Lancet 1986;1:116–8.
3. Vincent A, Leite MI. Neuromuscular junction autoimmune
disease: muscle specific kinase antibodies and treatments 
for myasthenia gravis. Curr Opinion Neurol 2005;18:
519–25.
4. Hoch W, McConville J, Helms S, et al. Auto-antibodies to
the receptor tyrosine kinase MuSK in patients with myas-
thenia gravis without acetylcholine receptor antibodies.
Nat Med 2001;7:365–8.
5. Evoli A, Tonali PA, Padua L, et al. Clinical correlates 
with anti-MuSK antibodies in generalized seronegative
myasthenia gravis. Brain 2003;126:2304–11.
6. Vincent A, Bowen J, Newsom-Davis J, et al. Seronegative
generalized myasthenia gravis: clinical features, antibodies,
and their targets. Lancet Neurol 2003;2:99–106.
7. Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects
of MuSK antibody positive myasthenia gravis. Neurology
2003;60:1978–80.
8. Scuderi F, Marino M, Colonna L, et al. Anti-p110 auto-
antibodies identify a subtype of “seronegative” myasthe-
nia gravis with predominant oculobulbar involvement.
Lab Invest 2002;82:1139–46.
9. Lavrnic D, Losen M, Vujic A, et al. The features of myas-
thenia gravis with autoantibodies to MuSK. J Neurol
Neurosurg Psychiatry 2005;76:1099–102.
10. Ohta K, Shigemoto K, Kubo S, et al. MuSK antibodies in
AChR Ab-seropositive MG vs AChR Ab-seronegative MG.
Neurology 2004;62:2132–3.
11. Nemoto Y, Kuwabara S, Misawa S, et al. Patterns and
severity of neuromuscular transmission failure in seroneg-
ative myasthenia gravis. J Neurol Neurosurg Psychiatry
2005;76:714–8.
12. Yeh JH, Chen WH, Chiu HC, et al. Low frequency of
MuSK antibody in generalized seronegative myasthenia
gravis among Chinese. Neurology 2004;62:2131–2.
13. Chiu HC, Vincent A, Newsom-Davis J, et al. Myasthenia
gravis: population difference in disease expression and
acetylcholine receptor antibody titers between Chinese
and Caucasians. Neurology 1987;37:1854–7.
14. Chen WH, Chiu HC, Hseih RP. Association of HLA-
Bw46,DR9 haplotype in Chinese juvenile myasthenia 
patients. J Neurol Neurosurg Psychiarty 1993;56:382–5.
15. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia
gravis: recommendations for clinical research standards.
Neurology 2000;55:16–23.
16. Lee JY, Sung JJ, Cho JY, et al. MuSK antibody-positive,
seronegative myasthenia gravis in Korea. J Clin Neurosci
2006;13:353–5.
